Skip to main content
Clinical Trials/NL-OMON40335
NL-OMON40335
Completed
N/A

Epigenetic biomarkers to predict psoriasis disease progression * towards tailored therapy. - Psoriasis Epigenetics

Maastricht Universitair Medisch Centrum +0 sites9 target enrollmentTBD

Overview

Phase
N/A
Intervention
Not specified
Conditions
psoriasis
Sponsor
Maastricht Universitair Medisch Centrum +
Enrollment
9
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Observational invasive

Investigators

Sponsor
Maastricht Universitair Medisch Centrum +

Eligibility Criteria

Inclusion Criteria

  • For psoriasis patients:
  • \- Age: \>18 years old
  • \- No systemic therapy for psoriasis
  • \- Clinical diagnosis: Psoriasis Vulgaris or Psoriasis Guttata (The diagnosis will be confirmed by a dermatologist)
  • \- Topical therapy is OK if it IS possible to stop for 3 weeks;For the control group:
  • \- Age: \>18 years old
  • \- No generalised skin disease

Exclusion Criteria

  • For psoriasis patients:
  • \- Age: \<18 years old
  • \- Systemic therapy for psoriasis
  • \- Juvenile psoriasis
  • \- Not meeting the inclusion criteria
  • \- Excessive scar formation or keloid in medical history
  • \- Other (skin) disease that could influence the psoriasis
  • \- Minors or incapacitated subjects
  • \- Allergic reaction to lidocaine in medical history
  • \- Topical therapy if it is NOT possible to stop for 3 weeks;For the control group:

Outcomes

Primary Outcomes

Not specified

Similar Trials